Aardvark Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	5.31	2.17	2.7
Research & Development	17.36	4.48	7.17
Operating Expenses	22.79	7.42	10.36
Operating Income	-22.79	-7.42	-10.36
Interest & Investment Income	2.41	1.42	0.12
EBT Excluding Unusual Items	-20.37	-5.99	-10.24
Gain (Loss) on Sale of Investments	-0.22	-1.22	-2.32
Asset Writedown	-	-	-1
Pretax Income	-20.59	-7.21	-13.56
Net Income	-20.59	-7.21	-13.56
Net Income to Common	-20.59	-7.21	-13.56
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change (YoY)	0.90%	1.78%	-
EPS (Basic)	-5.15	-1.82	-3.49
EPS (Diluted)	-5.15	-1.82	-3.49
Free Cash Flow	-18.2	-5.82	-10.54
Free Cash Flow Per Share	-4.55	-1.47	-2.71
EBITDA	-22.77	-	-
D&A For EBITDA	0.02	-	-
EBIT	-22.79	-7.42	-10.36

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q